SHYNDEC(SH:600420)2015-10-29 16:00Financial Performance - Net profit attributable to shareholders rose by 12.72% to CNY 140,685,716.76 for the first nine months of the year[7]. - Operating revenue for the first nine months reached CNY 2,100,006,834.19, reflecting a growth of 3.95% year-on-year[7]. - Total operating revenue for Q3 2023 was approximately ¥657 million, a slight increase of 1.97% compared to ¥649 million in Q3 2022[27]. - Operating profit for Q3 2023 reached approximately ¥41.87 million, up 10.5% from ¥37.75 million in Q3 2022[28]. - Net profit for Q3 2023 was approximately ¥37.69 million, representing a 14.5% increase from ¥32.73 million in Q3 2022[28]. - The total profit for Q3 2023 was approximately ¥53.08 million, an increase of 30% from ¥40.80 million in Q3 2022[28]. - Basic earnings per share for Q3 2023 were ¥0.0623, down from ¥0.0789 in Q3 2022[29]. - Total comprehensive income amounted to 9,470,123.37 RMB for the quarter[30]. - Basic and diluted earnings per share were both 0.0329 RMB[30]. Assets and Liabilities - Total assets increased by 9.40% to CNY 4,167,147,771.01 compared to the end of the previous year[7]. - Current liabilities rose to CNY 1,359,475,470.18, up from CNY 980,038,749.97, indicating a significant increase of about 38.7%[21]. - Long-term borrowings decreased to CNY 1,088,500,000.00 from CNY 1,232,600,000.00, reflecting a reduction of approximately 11.7%[21]. - The total liabilities increased to CNY 2,644,824,256.78 from CNY 2,417,064,054.70, marking an increase of approximately 9.4%[21]. - The total equity attributable to shareholders increased to CNY 1,249,600,272.91 from CNY 1,167,096,042.19, reflecting a growth of about 7.1%[21]. Cash Flow - Cash flow from operating activities decreased by 2.72% to CNY 167,013,843.35 compared to the same period last year[7]. - Cash flow from financing activities decreased by 92.83% to $37,167,062.47, due to reduced net borrowings and increased interest payments[13]. - Cash inflow from operating activities totaled 2,064,955,705.72 RMB, down from 2,212,335,668.31 RMB year-on-year[33]. - Cash outflow from operating activities was 1,897,941,862.37 RMB, compared to 2,040,659,588.70 RMB in the same period last year[33]. - Net cash flow from investing activities was -164,218,499.33 RMB, reflecting a significant decrease from -660,047,470.20 RMB year-on-year[34]. - The ending balance of cash and cash equivalents was 407,711,721.38 RMB, compared to 421,804,965.74 RMB at the end of the previous year[34]. Investments and Expenses - Research and development expenses increased by 193.42% to CNY 47,033,989.67, indicating a significant investment in new technologies[12]. - Financial expenses increased by 94.63% to $55,167,092.49, as all interest on post-project borrowings was capitalized to expenses[13]. - The company reported an investment income of approximately ¥2.97 million in Q3 2023, compared to a loss of ¥0.02 million in Q3 2022[27]. - The company received government subsidies amounting to CNY 11,297,909.45, which are closely related to its normal business operations[9]. Market Strategy and Shareholder Information - The number of shareholders reached 17,231, with the top ten shareholders holding a combined 61.68% of shares[10]. - The company plans to continue expanding its market presence and investing in innovative products and technologies[12]. - The company is focused on expanding its market presence by developing non-cephalosporin and non-penicillin pharmaceuticals, aiming to enhance its product offerings[15]. - The company has committed to maintaining a cash dividend distribution of no less than 30% of the average net profit over the last three years, subject to operational conditions[16]. - The company has committed to a cash dividend policy that prioritizes cash distributions when conditions allow, ensuring shareholder returns[16].